(
out of
43
reviews
)
Board Certification
|
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Nephrology)
|
Patient Rating
Patients consistently praise Dr. Dwyer for excellent bedside manner and clear, approachable communication. Reviewers highlight that he listens carefully, spends time addressing concerns, and explains kidney conditions and treatment options in ways that are easy to understand. Many describe him as professional, compassionate, and trustworthy, noting he makes them feel heard and involved in their care. Overall feedback emphasizes skillful, caring care and strong patient-centered communication.
Generated via Patient Reviews
4.9
/5
( out of
43 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Professor |
|---|---|
| Academic Divisions |
Nephrology & Hypertension
|
| Board Certification |
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Nephrology)
|
Education history
| Undergraduate | Mathematics - Brown University | Sc.B. |
|---|---|---|
| Undergraduate | Classics: Latin - Brown University | A.B. |
| Professional Medical | Medicine - Brown University School of Medicine | M.D. with Distinction |
| Residency | Internal Medicine - Mayo Clinic | Resident |
| Residency | Internal Medicine - Mayo Clinic | Chief Resident |
| Fellowship | Nephrology/Hypertension - Vanderbilt University | Clinical Fellow |
| Research Fellow | Nephrology/Hypertension - Vanderbilt University | Research Fellow |
Selected Publications
Journal Article
- Nissen SE, Wang Q, Nicholls SJ, Zerlasiran, et. a (2024). A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA,
- Brulotte M, Alvey JS, Casper TC, Cook LJ, Dwyer JP, VanBuren J (2024). A risk- based approached to source data monitoring and documenting monitoring findings. Contemporary clinical trials communications,
- Nissen SE, Wolski K, Watts GF, et a (2024). Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA, 18(331), 1534¿1543.
- Cooper M, Cherney DZI, Greene TH, Heerspink HJL, Jardine M, Lewis JB, Wong MG, Baquero E, Heise M, Jochems J, Lanchoney D, Liss C, Reiser D, Scotney P, Velkoska E, Dwyer J (2024). Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial. Journal of the American Society of Nephrology, 35(11), 1546-1557.
- Brulotte M, Alvey JS, Casper TC, Cook LJ, Dwyer JP, VanBuren J (2024). A risk-based monitoring approach to source data monitoring and documenting monitoring findings. Contemporary clinical trials, 143, 107581.
- Chertow GM, Heerspink HL, Mark PB, Dwyer JP, Nowicki M, Wheeler DC, Correa-Rotter R, Rossing P, Toto RD, Langkilde AM, Jongs (2024). Effects of Dapagliflozin in Patients with Membranous Nephropathy. Glomerular diseases, 4(1), 137-145.
- Rowan CG, Agiro A, Chan KA, Colman E, White K, Desai P, Dwyer J (2024). Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. Advances in therapy, 41(6), 2381-2398.
- Heerspink HJL, Greasley PJ, Ahlström C, Althage M, Dwyer JP, Law G, Wijkmark E, Lin M, Mercier AK, Sunnåker M, Turton M, Wheeler DC, Ambery (2024). Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial. Nephrology, dialysis, transplantation, 39(3), 414-425.
- Drawz PE, Lenoir KM, Rai NK, Rastogi A, Chu CD, Rahbari-Oskoui FF, Whelton PK, Thomas G, McWilliams A, Agarwal AK, Suarez MM, Dobre M, Powell J, Rocco MV, Lash JP, Oparil S, Raj DS, Dwyer JP, Rahman M, Soman S, Townsend RR, Pemu P, Horwitz E, Ix JH, Tuot DS, Ishani A, Pajewski N (2024). Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT. Clinical journal of the American Society of Nephrology, 19(2), 213-223.
- Lane K, Palm M, Marion E, Kay M, Thompson D, Stroud M, Boyle H, Hillery S, Nanni A, Hildreth M, Nelson S, Burr JS, Edwards T, Poole L, Waddy SP, Dunsmore SE, Harris P, Wilkins C, Bernard GB, Dean JM, Dwyer JP, Benjamin Jr, DK, Selker HP, Hanley DF, Ford (2023). Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network. Journal of clinical and translational science, 7(1), E131.
- Moura FA, Berg DD, Bellavia A, Dwyer JP, Mosenzon O, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Feinberg MW, Braunwald E, Morrow DA, Sabatine M (2023). Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes care, 46(10), 1-9.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH, SELECT Trial Investigator (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Epub, 389(24), 2221-2232.
- Cummins MR, Burr J, Young L, Yeatts SD, Ecklund DJ, Bunnell BE, Dwyer JP, VanBuren J (2023). Decentralized research technology use in multicenter clinical research studies based at U.S. academic research centers. Journal of clinical and translational science, 7(1), e250.
- Palm ME, Thompson DD, Edwards T, Swartz K, Herzog KA, Bansal S, Echalier B, DeHart KC, Denmark S, Wilson JL, Nelson S, Waddy SP, Dunsmore SE, Atkinson JC, Wiley K Jr, Hassani S, Dwyer JP, Hanley DF, Dean JM, Ford D (2023). The Trial Innovation Network Liaison Team: building a national clinical and translational community of practice. Journal of clinical and translational science, 7(1), e249.
- Dwyer JP, Agiro A, Desai P, Oluwatosin (2023). Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study. Advances in therapy, 40(11), 4777-4791.
- Palm ME, Edwards TL, Wieber C, Kay MT, Marion E, Boone L, Nanni A, Jones M, Pham E, Hildreth M, Lane K, McBee N, Benjamin DK Jr, Bernard GR, Dean JM, Dwyer JP, Ford DE, Hanley DF, Harris PA, Wilkins CH, Selker H (2023). Development, implementation, and dissemination of operational innovations across the trial innovation network. Journal of clinical and translational science, 7(1), e251.
- Harris PA, Dunsmore SE, Atkinson JC, Benjamin DK Jr, Bernard GR, Dean JM, Dwyer JP, Ford DF, Selker HP, Waddy SP, Wiley KL, Wilkins CH, Cook SK, Burr JS, Edwards TL, Huvane J, Kennedy N, Lane K, Majkowski R, Nelson S, Palm ME, Stroud M, Thompson DD, Busacca L, Elkind MSV, Kimberly RP, Reilly MP, Hanley DF, Trial Innovation Networ (2023). Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical Trials. JAMA network open, 6(10), e2336470.
- Moura FA, Berg DD, Bellavia A, Dwyer JP, Mosenzon O, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Feinberg MW, Braunwald E, Morrow DA, Sabatine M (2023). Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes care, 46(10), 1807-1815.
- Agiro A, Dwyer JP, Oluwatosin Y, Desai (2023). Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study. ClinicoEconomics and outcomes research, 15, 691-702.
- Dwyer JP, Agiro A, Desai P, Cremisi (2023). Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study. Expert review of pharmacoeconomics & outcomes research, 23(9), 1057-1066.
- Chu CD, Lenoir KM, Rai NK, Soman S, Dwyer JP, Rocco MV, Agarwal AK, Beddhu S, Powell JR, Suarez MM, Lash JP, McWilliams A, Whelton PK, Drawz PE, Pajewski NM, Ishani A, Tuot D (2023). Concordance between clinical outcomes in the Systolic Blood Pressure Intervention Trial and in the electronic health record. Contemporary clinical trials, 128, 107172.
- Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, Rozenberg A, Murphy SA, Zelniker TA, Langkilde AM, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Wilding JPH, McGuire DK, Bhatt DL, Leiter LA, Cahn A, Dwyer JP, Heerspink HJL, Sabatine M (2022). Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes care, 45(10), 2350-2359.
- Drawz PE, Rai NK, Lenoir KM, Suarez M, Powell JR, Raj DS, Beddhu S, Agarwal AK, Soman S, Whelton PK, Lash J, Rahbari-Oskoui FF, Dobre M, Parkulo MA, Rocco MV, McWilliams A, Dwyer JP, Thomas G, Rahman M, Oparil S, Horwitz E, Pajewski NM, Ishani (2022). Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study. Kidney360, 3(7), 1253-1262.
- Canoy D, Copland E, Nazarzadeh M, Ramakrishnan R, Pinho-Gomes AC, Salam A, Dwyer JP, Farzadfar F, Sundström J, Woodward M, Davis BR, Rahimi K, Blood Pressure Lowering Treatment Trialists' Collaboration, Blood Pressure Lowering Treatment Trialists Collaboratio (2022). Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. Heart (British Cardiac Society), 108(16), 1281-1289.
- Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC, DAPA-CKD Trial Committees and Investigator (2022). A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney international, 101(1), 174-184.
- Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz (2021). The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes care, 44(8), 1805-1815.
- The Blood Pressure Lowering Treatment Trialists¿ Collaboratio (2021). Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet (London, England), 398(10305), 1053-1064.
- Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG, SCORED Investigator (2021). Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. The New England journal of medicine, 384(2), 129-139.
- SPRINT Research Group., Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius W (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine, 384(20), 1921-1930.
- Cox ZL, Sarrell BA, Cella MK, Tucker B, Arroyo JP, Umanath K, Tidwell W, Guide A, Testani JM, Lewis JB, Dwyer J (2021). Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. Journal of cardiac failure,
- Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott S (2021). Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA cardiology, 6(7), 801-810.
- The Blood Pressure Lowering Treatment Trialists¿ Collaboratio (2021). Age and blood pressure stratified effects of blood pressure- lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual-level meta-analysis of 358,707 randomised participants. Lancet (Edizione Italiana), The, 10305(398), 1053-1064.
- Zuo Y, Cavalcante LB, Smelser JM, Sanghani N, Dwyer JP, Lewis JB, Fogo A (2021). Anti-Phospholipase A2 Receptor in Nonlupus Patients with Membranous Nephropathy and Crescents. Glomerular diseases, 2(2), 75-82.
- Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Górriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjöström CD, Langkilde AM, Heerspink HJ (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology, dialysis, transplantation, 35(10), 1700-1711.
- Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, DAPA-CKD Investigator (2020). Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology, dialysis, transplantation, 35(2), 274-282.
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigator (2020). Dapagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine, 383(15), 1436-1446.
- Burgner A, Ikizler TA, Dwyer J (2020). COVID-19 and the Inpatient Dialysis Unit: Managing Resources during Contingency Planning Pre-Crisis. Clinical journal of the American Society of Nephrology, 15(5), 720-722.
- Drawz PE, Agarwal A, Dwyer JP, Horwitz E, Lash J, Lenoir K, McWilliams A, Oparil S, Rahbari-Oskoui F, Rahman M, Parkulo MA, Pemu P, Raj DS, Rocco M, Soman S, Thomas G, Tuot DS, Whelton PK, Pajewski N (2020). Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice. JAMA internal medicine, 180(12), 1655-1663.
- Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee and Investigator (2019). Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 139(3), 366-375.
- Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott S (2019). Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 139(22), 2528-2536.
- Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott S (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 139(22), 2516-2527.
- Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, Dwyer JP, EPIC Study Grou (2019). Once-Daily Plazomicin for Complicated Urinary Tract Infections. The New England journal of medicine, 380(8), 729-740.
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE'TIMI 58 Investigator (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 380(4), 347-357.
- Waguespack DR, Dwyer J (2019). Assessment of Blood Pressure: Techniques and Implications From Clinical Trials. Advances in chronic kidney disease, 26(2), 87-91.
- Rahimi K, Canoy D, Nazarzadeh M, Salimi-Khorshidi G, Woodward M, Teo K, Davis BR, Chalmers J, Pepine CJ, The Blood Pressure Lowering Treatment Trialists¿ Collaboratio (2019). Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). BMJ open, 9(5), e028698.
- Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz (2019). Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. The lancet. Diabetes & endocrinology, 7(8), 606-617.
- Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA, Chronic Kidney Disease Epidemiology Collaboratio (2019). Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. The lancet. Diabetes & endocrinology, 7(2), 128-139.
- Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene (2019). Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. Journal of the American Society of Nephrology, 30(8), 1523-1533.
- Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, Umanath K, Rahbari-Oskoui F, Porter AC, Pisoni R, Lewis CE, Lewis JB, Lash JP, Katz LA, Hawfield AT, Haley WE, Freedman BI, Dwyer JP, Drawz PE, Dobre M, Cheung AK, Campbell RC, Bhatt U, Beddhu S, Kimmel PL, Reboussin DM, Chertow GM, SPRINT Research Group (2018). Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis, 71(3), 352-361.
- Shapiro BP, Ambrosius WT, Blackshear JL, Cushman WC, Whelton PK, Oparil S, Beddhu S, Dwyer JP, Gren LH, Kostis WJ, Lioudis M, Pisoni R, Rosendorff C, Haley WE, SPRINT Research Group (2018). Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension (Dallas, Tex., 71(6), 1064-1074.
- Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach (2018). Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney international, 93(6), 1397-1408.
- Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee Investigator (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet (London, England), 392(10161), 2269-2279.
- Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA-TIMI 61 Steering Committee and Investigator (2018). Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. The New England journal of medicine, 379(12), 1107-1117.
- Nogid B, Lacy MK, Jacobs M, Bruss J, Dwyer (2018). Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials. Pharmacotherapy, 38(10), 990-998.
- Supiano MA, Lovato L, Ambrosius WT, Bates J, Beddhu S, Drawz P, Dwyer JP, Hamburg NM, Kitzman D, Lash J, Lustigova E, Miracle CM, Oparil S, Raj DS, Weiner DE, Taylor A, Vita JA, Yunis R, Chertow GM, Chonchol (2018). Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. PloS one, 13(9), e0203305.
- Umanath K, Greco B, Jalal DI, McFadden M, Sika M, Koury MJ, Niecestro R, Hunsicker LG, Greene T, Lewis JB, Dwyer J (2017). The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis¿. Clinical nephrology, 87 (2017)(3), 124-133.
- Drawz PE, Pajewski NM, Bates JT, Bello NA, Cushman WC, Dwyer JP, Fine LJ, Goff DC Jr, Haley WE, Krousel-Wood M, McWilliams A, Rifkin DE, Slinin Y, Taylor A, Townsend R, Wall B, Wright JT, Rahman (2017). Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension (Dallas, Tex., 69(1), 42-50.
- Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, SPRINT Research Grou (2017). Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. The New England journal of medicine, 377(8), 733-744.
- Jalal D, McFadden M, Dwyer JP, Umanath K, Aguilar E, Yagil Y, Greco B, Sika M, Lewis JB, Greene T, Goral (2017). Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. Hemodialysis international. International Symposium on Home Hemodialysis, 21(2), 243-249.
- Weldegiorgis M, de Zeeuw D, Dwyer JP, Mol P, Heerspink HJ (2017). Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?. Clinical journal of the American Society of Nephrology, 12(10), 1595-1600.
- Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J, Focal Segmental Glomerulosclerosis Study Grou (2017). A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. Kidney international reports, 2(5), 800-810.
- Chang TI, Evans G, Cheung AK, Cushman WC, Diamond MJ, Dwyer JP, Huan Y, Kitzman D, Kostis JB, Oparil S, Rastogi A, Roumie CL, Sahay R, Stafford RS, Taylor AA, Wright JT Jr, Chertow GM, SPRINT Study Research Grou (2016). Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. Hypertension (Dallas, Tex., 67(3), 550-5.
- Tamura MK, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C, Jahanian H, Zaharchuk G, SPRINT Study Research Grou (2016). Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology, 86(13), 1208-16.
- Dwyer J (2016). We Give Too Much Intravenous Iron. Seminars in dialysis, 29(4), 309-11.
- van der Sande NG, Dorresteijn JA, Visseren FL, Dwyer JP, Blankestijn PJ, van der Graaf Y, Heerspink H (2016). Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes, obesity & metabolism, 18(11), 1120-1127.
- Schievink B, Kröpelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, Vemer P, de Zeeuw D, Lambers Heerspink H (2016). Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes, obesity & metabolism, 18(1), 64-71.
- Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group (2015). The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Am J Kidney Dis, 66(3), 479-88.
- Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP, Collaborative Study Group (2015). Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol, 26(10), 2578-87.
- Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study Group (2015). Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol, 26(2), 493-503.
- SPRINT Research Group., Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius W (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine, 373(22), 2103-16.
- Dwyer JP, Greco BA, Umanath K, Packham D, Fox JW, Peterson R, Broome BR, Greene LE, Sika M, Lewis J (2015). Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. Nephron, 129(1), 22-8.
- Rodby RA, Umanath K, Niecestro R, Bond TC, Sika M, Lewis J, Dwyer JP, Collaborative Study Grou (2015). Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Drugs in R&D, 15(3), 271-9.
- Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP, Collaborative Study Grou (2015). Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert review of pharmacoeconomics & outcomes research, 15(3), 545-50.
- Coffin ST, Waguespack DR, Haglund NA, Maltais S, Dwyer JP, Keebler M (2015). Kidney dysfunction and left ventricular assist device support: a comprehensive perioperative review. Cardiorenal medicine, 5(1), 48-60.
- McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D (2014). Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis, 64(5), 714-22.
- Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D (2014). Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis, 63(2), 244-50.
- Haglund NA, Feurer ID, Dwyer JP, Stulak JM, DiSalvo TG, Keebler ME, Schlendorf KH, Wigger MA, Maltais S (2014). Does renal dysfunction and method of bridging support influence heart transplant graft survival? Ann Thorac Surg, 98(3), 835-41.
- Umanath K, Lewis JB, Dwyer J (2014). Optimizing blood pressure control in patients with nondiabetic glomerular disease. Advances in chronic kidney disease, 21(2), 200-4.
- Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK, SPRINT Study Research Grou (2014). The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clinical trials (London, England), 11(5), 532-46.
- Sinsakul M, Rodby R, Umanath K, Niecestro R, Dwyer J (2014). Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data. Expert review of clinical pharmacology, 7(6), 705-10.
- Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013). Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis, 61(5), 759-66.
- Hartle PM, Carlo ME, Dwyer JP, Fogo AB (2013). AKI in an HIV patient. J Am Soc Nephrol, 24(8), 1204-8.
- Elliott MR, Soto Soto JM, Haley WE, Fitzpatrick PM, Dwyer JP (2013). Labile hypertension: characteristics of a referred cohort. Clin Exp Hypertens, 35(3), 207-12.
- Dwyer JP, Lewis J (2013). Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook. The Medical clinics of North America, 97(1), 53-8.
- Umanath K, Morrison RS, Christopher Wilbeck J, Schulman G, Bream P, Dwyer J (2013). In-center thrombolysis for clotted AV access: a cohort review. Seminars in dialysis, 26(1), 124-9.
- Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Grou (2013). Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodialysis international. International Symposium on Home Hemodialysis, 17(1), 67-74.
- Umanath K, Niecestro R, Lewis JB, Dwyer J (2013). Ferric citrate: a novel phosphate-binding agent. Expert review of endocrinology & metabolism, 8(1), 13-19.
- Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ (2012). Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis, 59(1), 75-83.
- Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB, Collaborative Study Group (2012). Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol, 23(1), 131-6.
- Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC, Collaborative Study Group (2012). Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol, 23(1), 123-30.
- Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J, Collaborative Study Grou (2012). The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron. Clinical practice, 121(1-2), c25-9.
- Siew ED, Ikizler TA, Matheny ME, Shi Y, Schildcrout JS, Danciu I, Dwyer JP, Srichai M, Hung AM, Smith JP, Peterson J (2012). Estimating baseline kidney function in hospitalized patients with impaired kidney function. Clinical journal of the American Society of Nephrology, 7(5), 712-9.
- Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis J (2012). Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal medicine, 2(1), 1-10.
- Fatima H, Siew ED, Dwyer JP, Paueksakon (2012). Membranous glomerulopathy with superimposed pauci-immune necrotizing crescentic glomerulonephritis. Clinical kidney journal, 5(6), 587-90.
- Dwyer JP, Lewis JB (2011). Olmesartan to prevent the development of microalbuminuria: is it new? Is it true? Is it important? Am J Kidney Dis, 58(5), 700-3.
- Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I, Collaborative Study Group (2011). Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis, 58(5), 729-36.
- Basford AW, Lewis J, Dwyer JP, Fogo AB (2011). Membranous nephropathy with crescents. J Am Soc Nephrol, 22(10), 1804-8.
- Packham DK, Ivory SE, Reutens AT, Wolfe R, Rohde R, Lambers Heerspink H, Dwyer JP, Atkins RC, Lewis J, Collaborative Study Grou (2011). Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. Nephron. Clinical practice, 118(4), c331-8.
- Elliott MR, Cortese C, Moreno-Aspitia A, Dwyer JP (2010). Plasma cell dyscrasia causing light chain tubulopathy without Fanconi syndrome. Am J Kidney Dis, 55(6), 1136-41.
- Bridges MD, St Amant BS, McNeil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM (2009). High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. AJR Am J Roentgenol, 192(6), 1538-43.
- Umana IE, Dwyer J (2009). Vicarious contrast excretion by the gallbladder in contrast nephropathy. Kidney international, 75(4), 446.
- Dwyer JP, Greco BA, Lewis J (2009). Evaluation of renal artery stenosis in dialysis patients. Seminars in dialysis, 22(5), 519-23.
- Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez J (2009). Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. The AIDS reader, 19(3), 114-21.
- Lette F, Dwyer J (2008). The fluid craze. Lancet (London, England), 372(9641), 782-4.
- Dwyer JP, Yates KM, Sumner EL, Stone WJ, Wang Y, Koury MJ, Fogo AB, Zent (2007). Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy. Clinical nephrology, 67(3), 176-81.
- The Blood Pressure Lowering Treatment Trialists¿ Collaboratio Blood pressure lowering and risk of new-onset type 2 diabetes: an individual-level meta-analysis of 145,000 randomized participants. Lancet (London, England),
- Rowan CG, Agiro A, Chan KA, Colman E, White K, Desai P, Dwyer J Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3–4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. Advanced therapeutics,
Review
- Dwyer JP, Kelepouris (2023). New Directions in Phosphorus Management in Dialysis. Journal of renal nutrition, 33(1), 12-16.
- Heyman SN, Raz I, Dwyer JP, Weinberg Sibony R, Lewis JB, Abassi (2022). Diabetic Proteinuria Revisited: Updated Physiologic Perspectives. Cells, 11(18),
Book Chapter
- Huston HK, Dwyer J (2018). Advances in the Management of Hyperkalemia.
Conference Proceedings
- Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, James MT, Heerspink HJL, Pollock CA, Stevens PE, Tamura MK, Tonelli MA, Wheeler DC, Winkelmayer WC, Cheung M, Hemmelgarn BR, Conference Participant (2018). Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international, 93(6), 1281-1292.
Editorial
- Umanath K, Burgner A, Lewis JB, Dwyer JP (2014). Guidelines and Straitjackets: blood pressure targets in the era of the Eighth Joint National Committee. Am J Kidney Dis, 63(6), 895-9.
Letter
- McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, Jubb AM, Serio AW, Krause KM, Daikos GL, CARE Study Grou (2019). Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. The New England journal of medicine, 380(8), 791-793.
- Choma DP, Cavanaugh KL, Dwyer J (2010). Is it always wrong to perform futile CPR?. The New England journal of medicine, 362(21), 2036; author reply 2036-7.
- Dwyer JP, Cohen M (2005). Interns' work hours. The New England journal of medicine, 352(7), 726-8; author reply 726-8.
More time/focus or just leave it up to PA
Dr. Dwyer is a phenomenal dr.
Appreciated time spent to address my needs.
Very understanding.
He is one of the best doctors I've ever seen & believe me I've seen a few. He is a huge asset too your facility!!
Dr Dwyer is a pleasure to talk to and takes a great deal of time to explain my kidney function and disease.
He is friendly. helpful and experienced. I trust him
Very good visit with Dr. Dwyer. Highly recommend. He listens and obviously cares about his patients and explains things very well.
Dr Dwyer is compassionate, clear and professional.
Dr. Dwyer has been a pleasure to work with. He knows his stuff, and then some.
Listened and didn't rush
He explained things to me in a clear way.
Dr Dwyer is the best.
Great bedside manor!
Helpful to me as a patience with information to try to figure out my health problem and go forward.
Dr. Dwyer is the best I trust him he has treated me so good
Dr. Dwyer was a God sent. He is a brilliant doctor and very caring. I've been to many different doctors this past few months to find answers only to be felt judged. Dr. Dwyers listens and he made me feel heard and understood.
I was super impressed with Dr Dwyer. He was an active listener and carefully reviewed my unique health history. I am pleased with his approach and expertise. Very warm and caring.
Dr. Dwyer is amazing! Everything he has done for me has worked great. He listens and also gives you great information. I would follow him anywhere if he left the U.
Friendly and answered questions
Dr.Dwyer is the best he is so polite and caring what is happening to me and want to get to the bottom to bad there isn't more Dr. Like Dr. DWYER
very personable, courteous, and professional
He was very interested in having my share my concerns about my health.
Dr Dwyer is everything we could hope for in a Medical professional. He is knowledgeable, easy to understand and although he is very busy he makes patients feel like he is truly interested them and their treatment. You are so fortunate to have Dr, Dwyer.
Dr. Dwyer is knowledgeable, professional, caring and personable. We are lucky to have him as a strong leader at the University of Utah Health system.
Best care EVER! Recommend Dr Dwyer
Dr. Jamie Dwyer is very gentle and very caring. My wellbeing is first and foremost with him. He is amazing!
I feel that my future survival is to a great part dependent on my having Dr Dwyer as my doctor and being able to see him on a quarterly basis!
He was very professional while also being funny. I appreciated that as a way to best understand the medication I need to start (and we'll still see who wins the "I told you so" bet...
He was very personable and did show concern for my kidney health. I had a great improvement in the last 6 months and he was very pleased to see the change for the better. And for me to consider how every medication affects my kidney health. And to be aware of that every time I take my prescribed medications.
I think that he is a very friendly person and makes you feel comfortable and lets you know what's going on so that you can understand it.
Dr. Dwyer explained very well the things that I needed to know in my case. I liked how he elaborated it in the way that I can understand it. He's very true and really knows how to take care of his patients.
He is very personable and caring. He explained my kidney issues and the treatment options. He is an excellent doctor.
Very impressive knowledge and practical advice. He was extremely friendly. Listened to all my concerns with interest and addressed my plan of care well
Very friendly, really knows what he is doing. Really appreciate him. He is such a good Dr
Great doctor. Would recommend him to others.
Dr. Dwyer was professional,knowledgeable, caring and listened to my concerns.
Pleasant, competent, and thorough.
Excitement specified skills and assignment follow through
Listened to me exceptionally, and took my concerns into consideration in changing my meds.
Dr. Dwyer explains things in a way I understand and answers all of my questions